Department of Ophthalmology, Konyang University College of Medicine, Daejeon, South Korea.
Acta Diabetol. 2019 Jun;56(6):691-696. doi: 10.1007/s00592-019-01305-w. Epub 2019 Mar 1.
To evaluate the safety and efficacy of vitrectomy combined with an intraoperative dexamethasone (Ozurdex) implant in refractory diabetic macular edema (DME).
Patients who were diagnosed at our institution as having DME refractory to more than 6 months of non-surgical treatment and underwent intravitreal dexamethasone implantation combined with vitrectomy. All patients were followed up for more than 12 months. Best-corrected visual acuity (BCVA, logMAR), central macular thickness (CMT), and intraocular pressure at the initial visit and 1, 3, 4, 6, and 12 months after treatment were recorded.
Twenty-two eyes (22 patients) were included in this study. The mean preoperative BCVA was 0.68 and the mean CMT was 470.80 µm. The total number of the previous injections was 5.1 ± 1.6. The mean BCVA was significantly improved at all visits, and the mean CMT was also significantly reduced (p < 0.05). Sixteen eyes (73%) did not need additional implantations during follow-up.
Vitrectomy combined with an intraoperative dexamethasone (Ozurdex) implant was an effective and safe treatment option in patients with refractory DME.
评估玻璃体切割术联合术中地塞米松（Ozurdex）植入治疗难治性糖尿病黄斑水肿（DME）的安全性和疗效。
本研究纳入在我院诊断为 DME 且对超过 6 个月的非手术治疗无效，并接受玻璃体切割术联合玻璃体内地塞米松植入术的患者。所有患者均随访超过 12 个月。记录治疗前、治疗后 1、3、4、6 和 12 个月的最佳矫正视力（BCVA，logMAR）、中心黄斑厚度（CMT）和眼内压。
本研究共纳入 22 只眼（22 例患者）。术前平均 BCVA 为 0.68，平均 CMT 为 470.80µm。之前的注射总数为 5.1±1.6。所有随访时间点的平均 BCVA 均显著提高，平均 CMT 也显著降低（p<0.05）。16 只眼（73%）在随访期间无需额外植入。
对于难治性 DME 患者，玻璃体切割术联合术中地塞米松（Ozurdex）植入是一种有效且安全的治疗选择。
